Lifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)

Key Points

• Lifesci Capital has raised its Q3 2025 earnings per share (EPS) forecast for Zymeworks to ($0.54), an improvement from the previous estimate of ($0.55).
• Zymeworks reported a Q2 2025 EPS of $0.03, significantly exceeding consensus estimates of ($0.52), with revenue up 153.2% year-over-year.
• The company's stock currently holds an average rating of "Moderate Buy" and a price target of $21.43, with a strong institutional investor backing at nearly 92.89% ownership.

Zymeworks Inc. (NYSE:ZYME - Free Report) - Investment analysts at Lifesci Capital raised their Q3 2025 earnings per share (EPS) estimates for Zymeworks in a research note issued to investors on Monday, October 6th. Lifesci Capital analyst C. Zhu now forecasts that the company will post earnings of ($0.54) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. Lifesci Capital also issued estimates for Zymeworks' Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($1.42) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.85) EPS and FY2026 earnings at ($1.59) EPS.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.55. The company had revenue of $48.73 million during the quarter, compared to the consensus estimate of $17.18 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. Zymeworks's revenue for the quarter was up 153.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) earnings per share.

ZYME has been the topic of a number of other reports. HC Wainwright reissued a "neutral" rating and set a $13.00 price objective on shares of Zymeworks in a report on Thursday, July 3rd. Citigroup boosted their price objective on shares of Zymeworks from $19.00 to $22.00 and gave the company a "buy" rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $21.43.

Zymeworks Price Performance

Zymeworks stock opened at $16.68 on Thursday. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -11.12 and a beta of 1.51. Zymeworks has a 1-year low of $9.03 and a 1-year high of $17.70. The business has a fifty day moving average price of $14.96 and a 200-day moving average price of $13.20.

Institutional Investors Weigh In On Zymeworks

A number of hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in Zymeworks by 1,113.3% during the 1st quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock worth $77,000 after acquiring an additional 5,934 shares in the last quarter. SG Americas Securities LLC raised its stake in Zymeworks by 266.5% during the 1st quarter. SG Americas Securities LLC now owns 98,165 shares of the company's stock worth $1,169,000 after acquiring an additional 71,383 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Zymeworks by 12.7% during the 1st quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company's stock worth $138,000 after acquiring an additional 1,300 shares in the last quarter. Duncan Williams Asset Management LLC acquired a new stake in Zymeworks during the 1st quarter worth $263,000. Finally, CWM LLC raised its stake in Zymeworks by 1,091.2% during the 1st quarter. CWM LLC now owns 2,299 shares of the company's stock worth $27,000 after acquiring an additional 2,106 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.